Alaunos Therapeutics, Inc. (TCRT) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. Welcome to the Alanis Therapeutics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during that session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded, and if you require any assistance during the call, please press star 0. I would now like to hand the conference over to your speaker today, Mr. Alex Lobo, Investor Relations. Mr. Lobo, the floor is yours. Good morning, and welcome to the Alanos Therapeutics First Quarter 2022 Financial Results Conference Call and Audio Webcast. With me today is Kevin Boyle, Sr., Chief Executive Officer, Drew Deniger, Vice President of Research and Development, and Mike Wong, Vice President of Finance. Earlier this morning, Elanos issued a press release announcing financial results for the three months ended March 31st, 2022. We encourage everyone to read today's press release, as well as the Elanos quarterly report on Form 10Q for the quarter ended March 31st, 2022, which was filed this morning with the SEC. The company's press release and quarterly report will also be available on the Elanos website at elanos.com. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 1...